Home -> Law Blog Directory -> Patent Law Blogs -> IPBiz
(866) 635-2689 for Personal Injury or (866) 635-9402 for Criminal Defense
Find a Local Lawyer
Divorce (866) 635-6190
Personal Injury (866) 635-2689
Criminal Defense (866) 635-9402
Patent Law
: IPBizMylan, Novartis settle Hatch-Waxman case on Femara
By Lawrence B. Ebert, Esq.
A press release on tradingmarkets stated: Generic drugmaker Mylan said that under the agreement it had a patent licence allowing it to market its Letrozole tablets prior to the expiry of a U.S. patent on Femara.
Full post as published by IPBiz on December 02, 2008 (boomark / email).
Female Sales Reps Win Gender Case Against Novartis
Female Sales Reps Win Gender Case Against Novartis
Medicaid Fraud
GSK and Novartis Face $800 Million in Penalties
Verizon To Pay $52 Million To Settle
Verizon To Pay $52 Million To Settle "Pay as You Go" Data Charges FCC Investigation
Disabilities Groups Settle with Caltrans for $1.1 Billion
Disabilities Groups Settle with Caltrans for $1.1 Billion
Bayer to Pay $3.3 Million To Settle One A Day Vitamin Claims
Bayer to Pay $3.3 Million To Settle One A Day Vitamin Claims
Two Energy Companies Settle Whistleblower Qui Tam Suit
Two Energy Companies Settle Whistleblower Qui Tam Suit

Novartis Sues Mylan Over Generic Version of Lescol
A Welfare Analysis of Prohibitions on Reverse Payments in Pharmaceutical Patent Disputes
Hatch-Waxman Safe Harbor Doesnt Apply to Device Not Subject to FDA Approval
Covenant not to sue removes jurisdiction despite lingering Hatch-Waxman exclusivity issues







